Share This Page
Suppliers and packagers for CYTOMEL
✉ Email this page to a colleague
CYTOMEL
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379 | NDA AUTHORIZED GENERIC | Mylan Pharmaceuticals Inc. | 59762-1206-1 | 100 TABLET in 1 BOTTLE (59762-1206-1) | 2019-02-06 |
| King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379 | NDA AUTHORIZED GENERIC | Mylan Pharmaceuticals Inc. | 59762-1207-1 | 100 TABLET in 1 BOTTLE (59762-1207-1) | 2019-06-24 |
| King Pharms | CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379 | NDA AUTHORIZED GENERIC | Mylan Pharmaceuticals Inc. | 59762-1208-1 | 100 TABLET in 1 BOTTLE (59762-1208-1) | 2019-06-24 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: CYTOMEL
Introduction
Cytomel, generically known as liothyronine sodium, is a synthetic form of the thyroid hormone triiodothyronine (T3). It plays a critical role in managing hypothyroidism, myxedema coma, and other thyroid-related disorders. Its significance in both clinical settings and the pharmaceutical supply chain underscores the importance of reliable suppliers. This article provides a comprehensive overview of the key suppliers of Cytomel, examining market dynamics, manufacturing players, regulatory considerations, and implications for healthcare providers and distributors.
Market Overview
The global market for thyroid hormone medications, including Cytomel, has seen considerable growth driven by rising hypothyroidism prevalence, aging populations, and increasing awareness of thyroid disorders. The compound's synthesis involves sophisticated pharmaceutical manufacturing processes, often requiring specialized facilities and stringent regulatory oversight. As a result, top-tier suppliers with robust quality systems dominate the landscape, ensuring drug safety, consistency, and compliance with regulatory standards like the FDA in the US, EMA in Europe, and other national agencies.
Major Suppliers of Cytomel
1. Mylan (now part of Viatris)
Mylan, a prominent global pharmaceutical company, has historically been one of the primary suppliers of liothyronine sodium. Through its manufacturing facilities in the United States, Europe, and Asia, Mylan has supplied both branded and generic Cytomel products. The company’s extensive distribution network ensures availability in markets worldwide. Despite recent corporate restructuring under Viatris, the legacy of manufacturing quality and compliance persists.
2. GlaxoSmithKline (GSK)
GSK has been a notable player in the production of thyroid medications, including liothyronine sodium. Their well-established manufacturing infrastructure and rigorous quality controls make GSK a significant supplier, especially in European markets. However, GSK’s involvement in the Cytomel supply chain is less prominent compared to other APIs (Active Pharmaceutical Ingredients) manufacturers, often serving as a supplier of finished formulations.
3. Hikma Pharmaceuticals
Based in Jordan, Hikma Pharmaceuticals has become a key supplier of generic thyroid hormone drugs, including liothyronine. Their manufacturing plants in the Middle East and Europe are GMP-compliant, and Hikma has expanded its portfolio with critical niche medications like Cytomel. Hikma's focus on quality, affordability, and efficient distribution make it a strategic supplier for many markets.
4. Cipla
India’s Cipla is a major generic medication manufacturer with capabilities in producing liothyronine sodium. Cipla’s global footprint and cost-effective production have increased the accessibility of Cytomel, especially in developing countries. They adhere to international quality standards, making them a reliable supplier for countries with evolving healthcare infrastructure.
5. Other Notable Manufacturers
- Sanofi: Historically involved in the thyroid hormone segment, with some markets sourcing via Sanofi’s distribution channels.
- Laboratorios Andromaco: Based in Latin America, providing regional formulations and APIs.
- Teva Pharmaceutical Industries: A leading generic manufacturer with a portfolio that includes thyroid medication APIs.
Regulatory and Quality Considerations
Manufacturers supplying Cytomel must comply with strict Good Manufacturing Practice (GMP) standards, required by agencies like the FDA and EMA. Quality assurance involves rigorous testing for potency, purity, stability, and bioavailability. Unauthorized or substandard suppliers risk regulatory sanctions, product recalls, and harm to patient safety.
Given the critical nature of thyroid hormone replacement therapy, regulatory agencies frequently scrutinize suppliers for compliance and manufacturing consistency. Additionally, global supply chain disruptions—such as those caused by geopolitical tensions or pandemic-related constraints—may impact the availability of Cytomel, emphasizing the importance of diversified sourcing strategies.
Implications for Stakeholders
Healthcare providers and pharmacists depend on stable supplies from reputable manufacturers to ensure patient safety and treatment efficacy. Disruptions or influxes of counterfeit or substandard Cytomel can jeopardize treatment outcomes. Distributors should prioritize products from verified suppliers with validated quality standards. Regulators and policymakers must monitor the supply chain for counterfeit products and ensure transparency in sourcing.
Moreover, pharmaceutical companies seeking to enter the Cytomel market must navigate complex regulatory pathways, establish GMP-compliant manufacturing facilities, and develop licensing agreements with established suppliers to ensure compliance and market access.
Emerging Trends and Future Outlook
- Increasing Market Diversification: To mitigate risks associated with reliance on a limited number of suppliers, companies are exploring partnerships and licensing agreements with multiple manufacturers.
- Manufacturing Innovation: Advances in synthetic chemistry and manufacturing techniques are improving yield and purity of liothyronine API, reducing costs and enhancing supply stability.
- Regulatory Harmonization: The global push for harmonized standards may streamline approval processes, allowing faster market entry for new suppliers.
- Supply Chain Resilience: The COVID-19 pandemic accentuated vulnerabilities; hence, stakeholders are investing in supply chain resilience measures, including strategic stockpiling and diversification.
Key Takeaways
- Dominant Suppliers: Mylan/Viatris, Hikma Pharmaceuticals, Cipla, and GSK are among the leading manufacturers of Cytomel globally.
- Regulatory Compliance: Strict adherence to GMP standards is essential for production, influencing supplier reputation and market access.
- Supply Chain Risks: Geopolitical factors and pandemics pose risks to Cytomel availability; diversification and resilient supply strategies are critical.
- Market Dynamics: Growing demand for thyroid medications underscores the importance of reliable, high-quality suppliers.
- Emerging Opportunities: Innovation in manufacturing and regulatory harmonization pave the way for new entrants and enhanced supply stability.
FAQs
1. Who are the top global suppliers of Cytomel?
The leading suppliers include Mylan (Viatris), Hikma Pharmaceuticals, Cipla, and GSK, each with established manufacturing facilities and stringent quality controls.
2. What regulatory standards must suppliers of Cytomel meet?
Manufacturers must comply with GMP regulations set by agencies like the FDA, EMA, and equivalent authorities, ensuring product safety, potency, and purity.
3. Are there regional differences in Cytomel suppliers?
Yes. North America primarily sources from Mylan and GSK, whereas Asian and Middle Eastern markets often rely on Cipla and Hikma, reflecting regional manufacturing capabilities and regulatory environments.
4. How do supply chain disruptions affect Cytomel availability?
Disruptions due to geopolitical tensions, pandemics, or manufacturing issues can lead to shortages. Diversification and strategic stockpiling are vital mitigation measures.
5. What should healthcare providers consider when sourcing Cytomel?
Ensuring products are sourced from verified, GMP-compliant manufacturers and authorized distributors minimizes risks of counterfeit or substandard medication, safeguarding patient health.
References
[1] European Medicines Agency. (2022). Guidelines on the quality of thyroid hormone products.
[2] U.S. Food and Drug Administration. (2021). GMP standards for API manufacturing.
[3] IMS Health Reports. (2022). Global thyroid medication market analysis.
[4] Pharmaceutical Technology. (2023). Supply chain resilience in pharmaceutical manufacturing.
[5] MarketWatch. (2023). Growth trends in thyroid hormone therapy.
More… ↓
